Pancreatic cancer: Pancreatic tumour formation and recurrence after radiotherapy are blocked by targeting CD44

  title={Pancreatic cancer: Pancreatic tumour formation and recurrence after radiotherapy are blocked by targeting CD44},
  author={Natalie J. Wood},
  journal={Nature Reviews Gastroenterology \&Hepatology},
  • Natalie J. Wood
  • Published 21 January 2014
  • Medicine, Biology, Physics
  • Nature Reviews Gastroenterology &Hepatology
Pancreatic cancer: Pancreatic tumour formation and recurrence after radiotherapy are blocked by targeting CD44 

Expression of CD 44 in pancreatic cancer and its significance

Background: CD44 is a potentially interesting prognostic marker and therapeutic target in pancreatic cancer. The expression of CD44 has been reported to correlate with poor prognosis of pancreatic

Expression and significance of CD44 and p-AKT in pancreatic head cancer

CD44 was related to the distant metastasis and aggressive malignant behaviors of pancreatic head cancer and Cox proportional hazard model showed that CD44 and lymph node metastasis were independent prognostic factors.

Expression of CD 44 and prostate stem cell antigen and their prognostic significance in human pancreatic ductal adenocarcinoma

The data indicated that co-staining of CD44 and PSCA should be recommended in PDCA patients for predicting prognosis, and positive co-expression of CD 44 and P SCA was an independent indicator for PDCA prognosis.

CD44 Predicts Early Recurrence in Pancreatic Cancer Patients Undergoing Radical Surgery

High CA19-9 levels, CD44 H-scores and poor differentiation are independent predictors for ER in PDAC patients undergoing radical resection, therefore, the determination of CD44 expression might help in identifying patients at a high risk of ER for more aggressive treatment after radical surgery.

Immunohistochemical analysis of cancer stem cell markers in pancreatic adenocarcinoma patients after neoadjuvant chemoradiotherapy

This is the first report showing that NACRT may influence the expression frequencies of CD44, CD133 and ALDH1 in PA patients, and these expressions may be useful predictors of prognosis inPA patients who have received NAC RT.

ELK1 Enhances Pancreatic Cancer Progression Via LGMN and Correlates with Poor Prognosis

A new mechanism by which ELK1 promoted the progression of pancreatic cancer via LGMN and conferred poor prognosis is revealed, which was positively correlated with clinical stage, degree of differentiation and Lymph node infiltration.

CD44 SNP: A novel biomarker signature that predicts survival in resectable pancreatic ductal adenocarcinoma

This book aims to provide a history of visceral and Transplantation Surgery in Europe and investigates the role of blood transfusions in the development of central nervous system disorders.

Tuned near infrared fluorescent hyaluronic acid conjugates for delivery to pancreatic cancer for intraoperative imaging

By tuning HA molecular weight and the physicochemical properties of the conjugated moiety, in this case a NIRF probe, peritoneal biodistribution can be substantially altered to achieve optimized delivery to tumors intraoperative abdominal imaging.

Asparaginyl endopeptidase enhances pancreatic ductal adenocarcinoma cell invasion in an exosome-dependent manner and correlates with poor prognosis.

Data indicated that high AEP expression may be important for pancreatic carcinoma progression in an exosome-dependent manner, and that AEP may be an independent indicator of poor prognosis in patients with PDAC and may be a novel prognostic biomarker or therapeutic target in pancreato- carcinoma.

CD44 SNPrs187115: A Novel Biomarker Signature that Predicts Survival in Resectable Pancreatic Ductal Adenocarcinoma

CD44 SNPrs187115 can serve as a novel biomarker readily available at the time of PDAC diagnosis that identifies patients at risk for faster tumor progression and guide personalized treatment decisions and has the potential to significantly expand the pool of patients that would benefit from tumor resection.


Antibody against CD44s inhibits pancreatic tumor initiation and postradiation recurrence in mice.

The TIC marker CD44s is up-regulated in human pancreatic tumors and associated with patient survival time, and strategies to target CD 44s cab be developed to block pancreatic tumor formation and post-radiotherapy recurrence in patients.